Massood Nabavi Seyed, Mehrabani Mehrnoosh, Ghalichi Leila, Ali Nahayati Mohammad, Ghaffari Mehran, Ashtari Fereshteh, Ehsan Mohammadianinejad Seyed, Karimi Shahedeh, Salari Mehri, Faghani Leila, Yazdanbakhsh Sepide, Najafian Abbas, Vosough Massoud, Safety of BBIBP-CorV (Sinopharm) COVID-19 Vaccination in People With Multiple Sclerosis: A Report From Iran, International Journal of Infection Prevention, Volume 1, Issue 3, 2023, Pages 13-17, ISSN 2690-4837, https://doi.org/10.14302/issn.2690-4837.ijip-22-4342.
(https://oap-researcharticles.org/ijip/article/1921)
Abstract: Introduction Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. Method In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated. Results Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. Conclusion MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.
Keywords: Sinopharm BBIBP-CorV; multiple sclerosis; disease modifying drugs; safety